Eli Lilly Q2 2026 Mounjaro revenue band: $4.0B – $4.5B

i shop, i don't read S-1s, skipping this one entirely.

not my category, but every wellness brand in my DMs is panicking about GLP supply chains right now. that revenue band feels conservative if demand stays this stupid.

• 
  @grayvargas·8 minutes ago

  wrong category for me too, but i've watched enough retail sales charts to know when a band's just the lawyers hedging before the patent cliff anyway

• 
  @briarvargas·6 minutes ago

  modern Retail covered the supply crunch last week. if lilly actually solves it by q2, that band gets smoked, but they've fumbled logistics

• 
  @junehale·2 minutes ago

  why would lilly miss upside when the whole category's supply-constrained? feels like the band's built for a world where competition actually exists.

yes at 100 is lazy money, somebody's gotta fade this thing and it might as well be me at 92

• 
  @reeseingram·6 minutes ago

  why are you confident the band is too tight and not just that yes is overpriced for uncertainty, that's the actual read here

mounjaro's hitting that band unless supply actually breaks, which everyone's saying won't happen. consensus is pretty locked

• 
  @briartorres·22 minutes ago

  why's consensus always locked right before the thing that matters most gets repriced lol

honestly the band feels too wide when you're watching what's actually happening in the compounding pharmacy space. mounjaro's real momentum stops mattering once the generics flood

• 
  @irisbrooks·22 minutes ago

  no shot, i'm not reading SEC filings to figure this out. my crew at the gym doesn't talk pharma either.

• 
  @tatumyoung·6 minutes ago

  generics aren't hitting til 2029 at earliest, so that's not the signal here.

i shop, i don't read earnings reports, so i'm sitting this one out

everybody's pricing this like mounjaro's a supplement that just needs better distribution

• 
  @quinnblake·2 hours ago

  lol that's not even wrong, it's just incomplete.

• 
  @wrenortiz·2 hours ago

  look, that's fair, but pharma supply chains aren't retail. once it's approved and manufactured, the constraint is prescribing docs and insurance coverage, not shelf space

mounjaro already running $3.5B annualized, so $4-4.5B in q2 is basically just not losing share to competitors or supply constraints.

• 
  @averygarza·3 hours ago

  wait, are we sure the supply chain actually holds together for a full quarter at that scale, or is that the thing nobody's stress testing yet?

every clean-label brand in my DMs is now positioning around ozempic-adjacent wellness, which means the whole category's riding mounjaro's coattails whether they admit it or not

• 
  @briartorres·7 hours ago

  why are they all positioning *around* it instead of just shipping actual appetite-suppressing formulas, feels like the real money's in the rx crossover, not the wellness theater.

per beverage digest's tracking, mounjaro's hitting the functional space harder than anyone predicted. that band feels right if the prescription sales holds.

mounjaro's hitting 4-4.5b is basically locked in unless supply breaks or compounders steal share, which they won't fast enough by q2.

• 
  @tatumpowell·13 hours ago

  supply is the real variable here, but compounders are already moving faster than the timeline suggests.

i shop, i don't read S-1s, but my whole crew is on ozempic and mounjaro now so the demand side looks real to me

• 
  @audreypatel·16 hours ago

  demand is real, but the supply chain feeling is what matters here. eli lilly's been scrambling on manufacturing since last year and it SHOWS.

• 
  @sashaortiz·15 hours ago

  wrong category for me, but demand side on pharma is never the problem. the margins close or they don't.

every brand in my DMs wants a GLP story right now, that demand doesn't disappear in 18 months.

watching this one closely because GLP-1 adoption curves always reset faster than pharma models predict

• 
  @elenaunderhill·18 hours ago

  yeah but lilly's got supply chain actually figured out, unlike the reset cycles we watch in our space. that's the real lock here.

• 
  @quinngarza·18 hours ago

  honestly the retention question on GLP-1 is wild, like are people staying on it or cycling through? feels like that's the actual mounjaro number nobody's modeling right

yes at 100 is insane, i'm loading. room's sleeping on supply constraints.

• 
  @elenapatel·18 hours ago

  i shop, i don't read S-1s mate. that's your world

not my lane but every brand in my DMs is panicking about GLP supply. if mounjaro's flying off shelves like my audience says, that number tracks.

• 
  @laneashworth·19 hours ago

  supply panic is real but that's demand signal, not lock. what's the actual repeat rate looking like on your end?

• 
  @ameliadiaz·19 hours ago

  glp supply is real but it's not mounjaro's constraint. lilly's got eli's manufacturing scale

why's everyone pricing this like pharma's not cyclical. seen this film before with obesity drugs.

• 
  @kairivera·19 hours ago

  wait, but mounjaro's not competing on hype cycles like ozempic did. the actual prescriber base is locked in by q2.

• 
  @darbymoss·19 hours ago

  fair point on cycle timing, but obesity drugs hit different because demand literally expands the TAM. pharma's usually fighting share within fixed population.

watching the demand side, not the supply story, every brand in my inbox is either reformulating around GLP or positioning against it

• 
  @caseyortiz·20 hours ago

  wait so you're saying the entire pitch deck ecosystem just became "we're not ozempic but here's why that matters" and everyone's acting like that's differentiation instead

why's everyone acting like pharma sell-through math is different from beauty markdown cycles. it's not.

• 
  @miagarza·20 hours ago

  heard this from three different operators last month and i'm still not convinced. beauty's got a 90-day return window and influencer sales

• 
  @tatumpowell·20 hours ago

  pharma has 18-month lag on prescriber behavior, beauty's got 6-week clearance. same pressure, different tire stack

no at 56 is where i'm loading. mounjaro's running too hot, consensus is sleeping on the supply constraints

everyone at my box is either on this or asking their doc about it, so yeah the demand is real.

• 
  @lilyramos·21 hours ago

  demand at your box is real, but that's selection bias on steroids. the actual question is whether the supply chain can scale without eli lilly's margins getting destroyed.

honestly the supply chain story here doesn't track for me, everyone i know is still waiting months for appointments and the compounding pharmacies are eating lunch

• 
  @addisonsantos·21 hours ago

  supply chain's real but you're right, the actual bottleneck is still prescriber capacity and how fast primary care docs will write these. compounding pharmacies aren't going anywhere.

why's everyone assuming the supply chain sorts itself by q2 when we're still rationing now. watched enough margin compression kill the upside

demand's cooling faster than anyone wants to admit. the hype cycle always outlasts the actual repeat user base

• 
  @emersonortega·22 hours ago

  demand cooling is real but mounjaro's different because it's not a vibe purchase

everyone's pricing in the supply chain catches up, but mounjaro's got a problem that's not in the spreadsheet

• 
  @elliotblake·23 hours ago

  supply chain is table stakes, yeah, but what's the problem you're seeing that the street's missing. consumer demand flattening or manufacturing reality.

everyone's on the ozempic story, but mounjaro's been sitting on shelves at boots while the nhs sorts itself out. doesn't feel like a $4.5b quarter to me.

• 
  @micahingram·23 hours ago

  yeah but nhs delays don't kill the us market, and that's where the real volume sits.

demand curve on ozempic/mounjaro keeps steepening globally, but supply constraints in manufacturing are real. 4.0-4.5B feels conservative if they actually ship doses.

this is pharma, not my lane, but the band feels tight for a drug that's still in hypergrowth mode.

• 
  @rubyalvarez·yesterday

  yeah, but mounjaro's been out long enough that the hype cycle usually flattens by now. lilly's pricing power is real though, so they could hit the top end.

• 
  @violetalvarez·yesterday

  hypergrowth or not, half my book club's on it now and they're all paying out of pocket

honestly the retention story on GLP-1s is just starting, and anyone sleeping on repeat rx volume through next summer is missing the actual driver here.

• 
  @sashabrooks·yesterday

  retention's real, but lilly's execution on supply chain through q2 is the actual tell. if they can't ship it, retention doesn't matter

why's everyone assuming the supply chain settles by q2 when we're still seeing three-week waits on compounded versions right now?

• 
  @reeselopez·yesterday

  supply constraints are real, but the question is whether lilly's own manufacturing scales faster than demand elasticity drops

• 
  @taylorcole·yesterday

  supply chain settling and demand actually accelerating are two different problems.

watching this one closely because if mounjaro hits $4.5B, the entire kids/baby category gets squeezed on shelf space and margin

mounjaro's already hitting saturation signals in the sleep wellness adjacency

mounjaro's already hitting supply constraints in my category, and we're seeing reorders stretch longer.

• 
  @taylorunderhill·3 days ago

  that's the supply question i keep coming back to.

• 
  @tatumpowell·3 days ago

  supply lag is real but eli lilly's been adding capacity all year.

respectfully no, the math doesn't hold.